Header Logo

Connection

VIVEK SUBBIAH to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Carcinoma, Non-Small-Cell Lung.
VIVEK SUBBIAH
Connection Strength
5.411
Carcinoma, Non-Small-Cell Lung
  1. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types. Clin Cancer Res. 2024 02 16; 30(4):836-848.
    View in: PubMed
    Score: 0.279
  2. Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases. Cancer. 2024 02 15; 130(4):530-540.
    View in: PubMed
    Score: 0.274
  3. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 10 02; 83(19):3159-3161.
    View in: PubMed
    Score: 0.272
  4. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book. 2023 May; 43:e404770.
    View in: PubMed
    Score: 0.264
  5. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Pharmacol Ther. 2023 02; 242:108344.
    View in: PubMed
    Score: 0.259
  6. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. JAMA Netw Open. 2022 11 01; 5(11):e2239874.
    View in: PubMed
    Score: 0.256
  7. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 10; 23(10):1261-1273.
    View in: PubMed
    Score: 0.253
  8. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nat Commun. 2022 06 17; 13(1):3500.
    View in: PubMed
    Score: 0.249
  9. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol Cancer Ther. 2022 06 01; 21(6):871-878.
    View in: PubMed
    Score: 0.248
  10. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2022 05 02; 5(5):e2214046.
    View in: PubMed
    Score: 0.247
  11. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 05; 33(5):522-533.
    View in: PubMed
    Score: 0.243
  12. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. JAMA Netw Open. 2021 11 01; 4(11):e2134299.
    View in: PubMed
    Score: 0.238
  13. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. JAMA Netw Open. 2021 10 01; 4(10):e2126306.
    View in: PubMed
    Score: 0.237
  14. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021 09 15; 19(1):209.
    View in: PubMed
    Score: 0.236
  15. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 12; 7(12):1074-1088.
    View in: PubMed
    Score: 0.235
  16. Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res. 2021 08 01; 27(15):4160-4167.
    View in: PubMed
    Score: 0.232
  17. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
    View in: PubMed
    Score: 0.223
  18. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824.
    View in: PubMed
    Score: 0.220
  19. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141.
    View in: PubMed
    Score: 0.186
  20. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1419-20.
    View in: PubMed
    Score: 0.161
  21. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer. 2015 Jul; 89(1):76-9.
    View in: PubMed
    Score: 0.152
  22. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023 10; 20(10):664-677.
    View in: PubMed
    Score: 0.067
  23. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2023 01 10; 41(2):385-394.
    View in: PubMed
    Score: 0.063
  24. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. Oncologist. 2022 02 03; 27(1):22-29.
    View in: PubMed
    Score: 0.061
  25. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 07; 22(7):959-969.
    View in: PubMed
    Score: 0.058
  26. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021 05; 96:102179.
    View in: PubMed
    Score: 0.057
  27. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.054
  28. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849.
    View in: PubMed
    Score: 0.047
  29. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20; 373(8):726-36.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.